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A series of high-pressure liquid chromatographic (hplc) procedures are described for 
the separation of all major and most minor catecholamine metabolites present in human 
urine. The amines and metabolites are first concentrated and partially purified by traditional 
methods, ion-exchange and alumina chromatography. Final separations are then performed 
with hplc. Our system is specifically designed to study dopamine Phydroxylation in vivo. 
[3H]Dopamine is administered intravenously to human subjects, and then all the excreted 
[3H]dopamine metabolites and 13H]norepinephrine metabolites are separated and assayed. 
The high degree of resolution achieved with hplc makes it possible to separate the small 
population of [3H]norepinephrine metabolites from the much larger population of [3H]- 
dopamine metabolites. The ratio of total excreted [3H]norepinephrine metabolitesltotal 
excreted [3H]dopamine metabolites averages 0.029 2 0.005 in urine samples collected during 
the hrst 6 h following the administration of isotope. 
Dopamine /3-hydroxylase (EC 1.14.17.1; 
3,4-dihydroxyphenylethylamine, ascorbate: 
oxygen oxidoreductase) (DBH)’ catalyzes 
the last step in NE biosynthesis (1) and is 
found mainly in catecholamine-containing 
tissues, such as sympathetic neurons, brain, 
and adrenal medulla (2,3). In noradrenergic 
neurons DBH is concentrated along with NE 
in the dense core vesicle of the nerve ter- 
minal and then released simultaneously with 
the neurotransmitter by a process of exo- 
1 To whom correspondence should be sent: Temple 
University Hospital, General Clinical Research Center, 
3401 N. Broad St., Philadelphia, Pa. 19140. 
* Abbreviations used: hplc, high-pressure liquid 
chromatography; THO, tritiated water; DBH, dopa- 
mine phydroxylase; NE, norepinephrine; NMN, 
normetanephrine; EPI, epinephrine; DA, dopamine; 
MN, metanephrine; MTA, methoxytyramine; DHPG, 
dihydroxyphenylglycol; DHPE, dihydroxyphenyletha- 
nol; DHMA, dihydroxymandelic acid; DOPAC, dihy- 
droxyphenylacetic acid; MHPG, 3-methoxy-4-hydroxy- 
phenylglycol: MHPE, 3-methoxy-4-hydroxyphenyleth- 
anal; VMA, 3-methoxy-4-hydroxymandelic acid; HVA, 
3-methoxy-4-hydroxyphenylacetic acid. 
cytosis (4). The limited tissue distribution 
of DBH has important implications for quan- 
titative studies of dopamine p-hydroxyla- 
tion in viva. Since systemically given 
catecholamines are not well taken up into 
the brain (5), any dopamine P-hydroxylation 
which occurs following [3H]DA administra- 
tion to the whole patient must derive from 
that small fraction of the [3HlDA which 
gains access to sympathetic neurons and 
adrenal medulla. Accordingly, a relatively 
low rate of dopamine /3-hydroxylation 
would be anticipated following the admin- 
istration of this substrate to whole ani- 
mals or humans. Presumably for this reason, 
some studies of dopamine metabolism in 
rats, guinea pigs, and dogs (6.7) have ignored 
the small pool of dopamine molecules which 
undergo P-hydroxylation. 
Quantitation of the rate of dopamine P-hy- 
droxylation in viva has been a technically 
difficult problem in the past because of dif- 
ficulties encountered in measuring the small 
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FIG. 1. Flow sheet for the separation of catecholamines and catecholamine metabolites. After the 
urine samples had been passed over Dowex 5OW-X4 and alumina, 50-ml aliquots were subjected to 
enzymatic hydrolysis and then recycled through Dowex 5OW-X4 and alumina for the assay of the 
conjugated deaminated catechols (DHPG, DHPE, DHMA, and DOPAC) and the total O-methylated 
deaminated metabolites (MHPG, MHPE, VMA, and HVA). Conjugated amines (NE, NMN, DA, 
and MTA) were assayed in separate aliquots of urine that were subjected to acid hydrolysis prior to 
Dowex SOW-X4 adsorption and elution was performed just as outlined for the free amines. 
pool of NE metabolites in the presence of 
the much larger pool of excreted DA me- 
tabolites. With the recent development of 
hplc, however @-IO), it is now possible to 
separate these two major families of cate- 
cholamine metabolites with relative ease. 
This is because the presence of a hydroxyl 
group on the P-position of these molecules 
significantly increases polarity and dramati- 
cally decreases hplc retention times. In this 
report, we describe a chromatographic sys- 
tem which combines hplc with standard 
techniques (ion-exchange and alumina chro- 
matography) and effectively separates all 
major and most minor catecholamine me- 
tabolites (Fig. 1). Using these methods, we 
have investigated dopamine P-hydroxyla- 
tion in man by quantitating the total pools 
of [3H]DA and [3H]NE metabolites excreted 
during the first 6 h after the intravenous 
administration of [3H]DA. 2 
MATERIALS AND METHODS 
Chemicals and equipment. All the cate- 
cholamines and catecholamine metabolites 
were purchased from Sigma except for 
MHPE which was purchased from Aldrich 
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and DHPE which was purchased from Regis. 
Dopamine with a tritium label in the p-posi- 
tion of the side chain (sp act 13.3 Cilmmol) 
was obtained from New England Nuclear 
(NET-131).3 Dowex 5OW-X4 (hydrogen form, 
200-400 mesh) was purchased from Bio- 
Rad Laboratories. Alumina was purchased 
from Chemical Manufacturing Corporation, 
Carle Place, New York. Glusulase (contain- 
ing 14,995 units of sulfatase/ml and 163,604 
units of glucuronidase/ml) was purchased 
from Endo Laboratories. High-pressure liquid 
chromatographic studies were performed 
with a single piston Altech pump, Model 
1lOA. A reversed-phase PBondapak Cl8 
column (3.9-mm i.d., 30-mm length) was 
purchased from Waters Associates. 
Experimental protocol. We included four 
men and three women, age range 35 through 
55, in this study. Most of the seven sub- 
jects who participated were in good health, 
though one had fasting hyperglycemia (blood 
sugar = 120) and a history of alcoholic 
hepatitis but normal liver function at the 
time of this experiment. Another patient had 
mild chronic obstructive pulmonary disease. 
A third patient was on insulin therapy for 
uncomplicated diabetes. The [3H]DA in- 
fusions (500 &i/70 kg) were performed at 
the Clinical Research Unit of the University 
of Michigan Hospital after informed consent 
had been obtained. The [3H]DA was passed 
through a 0.2-pm Millipore filter and then 
administered intravenously at 9:00 AM over 
a 2-min period. Urine was collected for the 
first 6 h after isotope administration in bot- 
tles containing 5 ml of 6 N HCl. The sub- 
’ This enzyme substrate is actually a mixture of two 
distinct enantiomers, (S)-[P-3H]DA whose hydroxyla- 
tion leads to the formation of 13H]NE and (R)-[/3-3H]DA 
whose hydroxylation leads to the formation of THO. 
In rats the rate at which THO is released from this 
substrate in rive can be used as an index of dopa- 
mine P-hydroxylation in the whole animal (11). We, 
thus, chose P-labeled DA for the present studies since 
we hope in the future to see whether the tritium re- 
lease principle developed in rats can be employed as 
an in ttitw assay of the human enzyme as well. 
jects remained upright and ambulatory dur- 
ing the urine collection period, though they 
were allowed to sit down for lunch and a 
5-min rest period each hour was allowed 
for those who needed it. The patients in- 
gested a regular diet. Cigarette smoking was 
not allowed. 
Separation of 3H-catecholamines and 
3H-O-methylated amines. The labeled amines 
were extracted from the urine with Dowex 
5OW-X4 in the hydrogen form. Ascorbic 
acid (0.2 ml of 2% solution) and disodium 
EDTA (1 .O ml of a 2% solution) were added 
to 48-ml aliquots of urine immediately prior 
to their analysis. The urine was adjusted 
to pH 6.5 and filtered through Whatman No. 
1 paper and the loss of volume was recorded. 
The sample was then divided into two equal 
portions each of which was then passed over 
a 0.7 x 4.5-cm Dowex SOW-X4 column. 
Partial fractionation of the amines was 
achieved by eluting the columns with in- 
creasing concentrations of HCl according 
to the method of Taylor and Laverty (12). 
The 1 N HCl fractions from the duplicate 
Dowex columns were pooled (total volume 
20 ml) and the t3H]NE was concentrated 
by passing this eluate over a 0.7 x 1.5~cm 
alumina column. The 3H-catecholamines 
were eluted with 0.2 N acetic acid (final vol- 
ume 3.5 ml). The [3H]NE was then sepa- 
rated from the [p-3H]DA by hplc. 
The 2 N HCl fractions from the duplicate 
Dowex columns were also pooled (total vol- 
umes 25 ml) and the [3H]NMN was concen- 
trated by passing this eluate over a second 
Dowex column. The 1 N HCl fraction of the 
second column was discarded, and then [3H]- 
NMN and [/3-3HlDA were eluted with 6.5 
ml of 4 N HCl. The 3H-amines in this fraction 
were then separated by hplc. 
The conjugated amines were assayed in 
separate aliquots of urine from which the 
free 3H-catecholamines were first removed 
by passage over alumina. The alumina til- 
trates were then subjected to acid hydrolysis 
under the conditions previously described 
(13). The conjugated 3H-catecholamines sulfonate (60 mg/liter) was used as the paired 
(now present as free compounds) were then ion reagent. After the DHPG had eluted, 
extracted by the Dowex 5OW-X4 columns the buffer was made 16% with respect to 
as described above for the unhydrolyzed methanol. Flow rate of the mobile phase 
samples. The rate of excretion of the 3H- was 0.8 ml/min. Retention times were de- 
conjugated 0-methylated amines could be termined by adding standard compounds and 
calculated by subtracting the rate of excre- then simultaneously monitoring optical 
tion of the free compounds (as measured in density and collecting fractions for radioac- 
the unhydrolyzed samples) from the rate of tivity determination as described for the 
excretion in the free and conjugated O-meth- amines. 
ylated amines (as measured in the hydrolyzed The 0.25 N HCl fraction was subjected 
samples). to hplc in 0.01 M H3P04 containing 20 mg 
Reversed-phase hplc of the amine frac- of tetraheptylammonium chloride as a paired 
tions was performed after equilibration of ion reagent. The flow rate of the mobile 
the columns with potassium monophosphate phase was 0.6 ml/min. After the DHMA had 
buffer (0.05 M) containing 5% methanol and eluted, we made the mobile phase 20% with 
60 mg/liter of sodium octyl sulfonate as a respect to methanol (to hasten the elution 
paired ion reagent (9). Mobile-phase flow of the DA metabolites). 
rate was 0.8 ml/min, and loo-p.1 aliquots Separation of 0-methylated deaminated 
were used for all analyses. Retention times metabolites. Urine which had been passed 
were determined by adding standard amines over Dowex 5OW-X4 (which removed the 
(0.10-0.30 mg/ml) to the samples, and moni- 3H-amines) and alumina (which removed 3H- 
toring ultraviolet absorbance at 254 nm. We catechols) was used for the assay of neutral 
simultaneously collected 30-s fractions, and and acidic 0-methylated metabolites (VMA, 
assayed the 3H-amines by liquid scintillation HVA, MHPG, MHPE). Aliquots of the 
spectrophotometry (Beckman LS-250). With alumina effluents (23 ml) were adjusted to 
older columns retention times could be im- pH 1.0 with 6 N HCl, and then the sample 
proved by using trichloroacetic acid (0.04 was transferred to a 50-ml glass-stoppered 
M) as the paired ion reagent as suggested centrifuge tube, saturated with solid NaCl, 
by Freed and Asmus (10). and an equal volume of ethyl acetate was 
Separation of deaminated catechols. The added. After mechanical shaking for 10 min, 
neutral and acidic catechol metabolites the samples were centrifuged (SOOOg, 10 
(DHPG, DHPE, DHMA, and DOPAC) were min) and the organic phase was transferred 
extracted from pooled effluents of the Dowex to a second set of tubes. The process was 
5OW-X4 columns (total volume 60 ml) by repeated with a second portion of ethyl ace- 
absorption at pH 8.6 onto alumina columns tate, and the organic phases from the two 
(0.7 x 3.0 cm). After an g-ml H,O wash, extractions were combined. Back extraction 
the neutral catechols (DHPG and DHPE) was performed by mechanically shaking the 
were eluted with 5.5 ml of 0.2 N acetic acid, pooled organic phases for 10 min with 4 ml 
and then the acidic catechols (DHMA and of 2.5 N NH,OH. The organic phase was 
DOPAC) were eluted with 5.5 ml of 0.25 discarded, and most of the NH, was removed 
N HCI (14). from the aqueous phase by allowing it to 
The 0.2 acetic acid fraction was subjected stand 24 h under a hood at room tempera- 
to reversed-phase hplc following preequili- ture. The sample was then adjusted to pH 
bration with 0.025 M potassium monophos- 4.5 with 1 N HCl and the alteration in vol- 
phate buffer, pH 4.75, containing citric acid ume recorded. Aliquots (100 ~1) of these 
(0.01 M) and 6% methanol. Sodium heptyl samples were analyzed by a hplc system 
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utilizing 0.025 M potassium monophosphate 
buffer containing 0.01 M citric acid and 60 
mg sodium heptylsulfonate per liter. The 
buffer was adjusted to pH 4.0 with 1 N NaOH. 
The initial methanol concentration was 12%; 
this was stepped up to 25% after the VMA 
and MHPG had eluted. 
Enzymatic hydrolysis and the assay of 
conjugated rnetabolites. The remaining alu- 
mina effluent (that not used for the assay 
of free deaminated, O-methylated metabo- 
lites) was subjected to enzymatic hydrolysis 
with glusulase according to the method of 
Bigelow et al. (15). Following precipitation 
of the phosphates and sulfates, the barium 
was removed by addition of saturated po- 
tassium carbonate as described by Shimizu 
and LaBrosse (16). Following the enzymatic 
hydrolysis and precipitation of proteins (15), 
the samples were recycled through Dowex 
5OW-X4 and alumina, just as described for 
the unhydrolyzed samples (see Fig. 1). We 
did not, however, elute the 3H-amines liber- 
ated in the enzymatic hydrolysis from the 
Dowex columns since these metabolites were 
assayed in separate aliquots of urine treated 
with acid hydrolysis as described above.4 
The neutral and acidic deaminated 3H-cate- 
chols, excreted as conjugates but now pres- 
ent as free compounds, were determined in 
their respective alumina eluate fractions. 
Aliquots of the final alumina effluent were 
used for the assay of total [3H]VMA, [3H]- 
HVA, [3H]MHPG, and [3H]MHPE as de- 
scribed above for the unhydrolyzed samples. 
All data are corrected for losses associ- 
ated with the gravity chromatography. Re- 
coveries were determined by measuring the 
OD,,, of standards carried through the above 
separation techniques. The recovery of all 
the compounds studied ranged between 50 
and 80%, except for NMN whose recovery 
’ We needed to employ both acid hydrolysis and 
enzymatic hydrolysis since the recovery of catechol- 
amine is higher after acid hydrolysis than after the 
enzymatic treatment, whereas the reverse is true for 
MHPG (13,15). 
through the two Dowex columns averaged 
only 40%. No correlation was made for 
losses associated with the hplc. We as- 
sumed the enzymatic hydrolysis was 85% 
effective (16) and the acid hydrolysis was 
100% effective. 
RESULTS 
Separation of 3H Catecholamines and 
3H-O-Methylated Amines 
The catecholamines and their O-meth- 
ylated derivatives could be readily separated 
by a single hplc system using potassium 
monophosphate buffer (0.05 M) containing 
5% methanol and sodium octylsulfonate (60 
mg/liter) as a paired ion reagent (9) (Fig. 2). 
When loo-p1 aliquots of the various acidic 
Dowex eluates were subjected directly to 
hplc, however, the radioactivity eluting in 
[3H]NE and [3H]NMN fractions was barely 
distinguishable from background for some 
of our samples. For this reason, we concen- 
trated the [3H]NE in the 1 N HCl fractions 
from two Dowex columns with a single alu- 
mina column, and the [3H]NMN in the 2 N 
HCl fractions of duplicate Dowex columns 
with another Dowex column. Using this 
protocol, we were able to detect free and 
conjugated [3H]NE in all of the samples 
analyzed. Only small amounts of radioac- 
tivity (see Table 1) eluted in free [3H]NMN 
fractions, even after the concentration step, 
and in some samples free [3H]NMN was 
barely detectable. Following acid hydroly- 
sis of the urine, however, a [3H]NMN peak 
could be readily distinguished in all of our 
samples (Fig. 2). Negligible amounts of ra- 
dioactivity eluted in those fractions that 
would have contained [3H]EPI and [3H]MN. 
Separation of Deaminated Catechols 
A mixture of standard neutral and acidic 
catechol metabolites (DHPG, DHPE, DHMA, 
and DOPAC) could be separated by a 
single hplc system (Fig. 3) using 0.025 M 
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FIG. 2. High-pressure liquid chromatographic separation of 3H-catecholamine and 3H-O-methylated 
amines. The 1 N HCl eluates from two Dowex 5OW-X4 columns were pooled, and the [3H]NE was 
concentrated by passing the resulting sample over alumina at pH 8.6 and eluting the 3H-amines in a 
small volume (3.5 ml) of 0.2 N acetic acid. A mixture of authentic amines were added to the resulting 
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TABLE I 
DISTRIBUTION OF 3H-C~~~~~~~~~~~~ 
DERIVATIVES AMONG THE [3H]DA 





























57.0 2 6.4 
0.0695 i 0.0149 
0.0334 k 0.0079 
0.0138 + 0.0039 
0.0297 -I- 0.0103 
0.0313 + 0.0110 
0.0467 + 0.0142 
0.0371 k 0.0010 
0.0066 2 0.0040 
0.790 r 0.111 
0.213 ? 0.033 
1.28 2 0.16 
6.54 + 0.97 
5.41 k I.14 
1.32 5 0.20 
3.33 k 0.83 
3.53 + 0.55 
2.51 + 0.55 
0.022 + 0.00s 
0.111 2 0.024 
22.61 + 2.80 
Trace 
45.4 2 3.7 
n All numbers represent the mean % + SE of the 
administered radioactivity excreted in the various 3H 
catecholamine metabolite pools. The data were ob- 
tained from seven control subjects on urine collected 
for the first 6 h after the intravenous administration of 
[3H]DA (SO0 @C/70 kg) given gradually over 2 min. 
potassium monophosphate buffer contain- 
ing citric acid (0.01 M) and an initial methanol 
concentration of 6% and a hnal methanol 
concentration of 16%. When the alumina 
columns were eluted directly with 0.25 N 
HCl (i.e., omitting the 0.2 N acetic acid 
wash), an unidentified early eluting peak of 
radioactivity obscured the t3H]DHMA peak. 
High-pressure liquid chromatography sys- 
tems that separated this unidentified peak 
from r3H]DHMA compromised the separa- 
tion of [3H]DHMA from [3H]DHPG. For 
this reason, we separated the [3H]DHPG 
from the [3H]DHMA by fractional elution of 
the alumina columns by increasingly strong 
acids; [3H]DHPG eluted in the 0.2 N acetic 
acid fraction and [3H]DHMA eluted in the 
0.25 N HCl fraction (14). The 0.2 N acetic 
acid fraction was then analyzed by the neu- 
tral hplc system described above, and the 
0.25 N HCl fraction was analyzed by an 
acidic hplc system (0.01 M H,PO, contain- 
ing 20 mg of tetraheptylammonium chloride/ 
liter) which retained the [3H]DHMA suffi- 
ciently to separate it from the interfering 
peak which eluted earlier (Fig. 4). Though 
this acidic system did not separate [3H]- 
DHPG from 13H]DHMA this was of no im- 
portance since the former eluted in the 0.2 N 
acetic acid fraction and minimal cross con- 
tamination of the 0.25 N HCl fraction oc- 
curred. Though the fractional elution of the 
alumina column effectively separated [3H]- 
DHPG from [3H]DHMA the corresponding 
[3HlDA metabolites, [3H]DHPE and [3H]- 
DOPAC, were not reliably separated by this 
protocol, so it was necessary to measure 
these labeled metabolites in the 0.2 N acetic 
acid fraction as well as the 0.25 N HCl frac- 
tion (Fig. 1). 
Using this protocol we were able to iden- 
tify free [3H]DHPG in five of seven samples; 
sample, and hplc was performed. ODzsa was monitored while fractions were collected for radioactivity 
determination. High-pressure liquid chromatography was performed with a mobile phase of 0.05 M 
potassium monophosphate buffer containing 5% methanol and sodium octylsulfonate as a paired ion 
reagent. The 2 N HCI Dowex SOW-X4 fractions from two columns were pooled and the 3H-amines 
concentrated by another Dowex SOW-X4 column. After washing this column with S ml of H,O and 
I4 ml of I N HCI, [3H]NMN and [p-3H]DA were eluted with 6.5 ml of 4 N HCI. High-pressure liquid 
chromatography was then performed as described for the 1 N HCI fractions. The 3 N HCI Dowex 
fractions were subjected directly to hplc. 
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FIG. 3. Neutral hplc system for separation 3H-de- 
aminated catechols. Aliquots (100 ~1) of the 0.2 N ace- 
tic acid eluate of the alumina columns were subjected 
to hplc following preequilibration of the column with 
0.025 M potassium phosphate buffer, pH 4.75, contain- 
ing citric acid (0.01 M) and 6% methanol. Sodium 
heptylsulfonate (60 mg/liter) was used as the paired ion 
reagent. Flow rate of the mobile phase was 0.8 ml/min. 
After [“H]DHMA and t3H]DHPG had eluted the mobile 
phase was made 16% with respect to methanol. 
following enzymatic hydrolysis of the alu- 
mina effluent and recycling of the sample 
through Dowex and alumina, hplc analysis 
of the 0.2 N acetic acid eluate revealed that 
a peak of radioactivity eluting with authentic 
DHPG could be identified in all seven sam- 
ples.5 Free [3H]DHMA was also identified 
in all of our samples, but following enzy- 
matic hydrolysis radioactivity coeluted with 
standard DHMA in only three of seven 
samples. 
5 Conjugated DHPG is a known metabolite of NE in 
rat brain (17,18), and has recently been identified in 
human urine by a mass spectroscopic method (19). 
Separation of 0-Methylated Deaminated 
Metabolites 
The neutral and acidic 0-methylated 
metabolites (VMA, HVA, MHPG, and 
MHPE) were separated by hplc using 0.025 
M potassium monophosphate buffer con- 
taining 0.01 M citric acid and 60 mg sodium 
heptylsulfonate per liter, pH 4.0, with an 
initial methanol concentration of 12% and a 
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FIG. 4. Acidic hplc system for separation of 3H-de- 
aminated catechol metabolites. Aliquots (100 ~1) of the 
0.25 N HCI alumina eluate were subjected to hplc fol- 
lowing preequilibration of the column with 0.01 M 
H3P01 containing 20 mg/liter of tetraheptylammonium 
chloride. After [3H]DHMA had eluted, the mobile 
phase was made 20% with respect to methanol. The 
flow rate was 0.6 mhmin. 
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FIG. 5. High-pressure liquid chromatographic separation of the 0-methylated deaminated metabolites. 
The 0-methylated deaminated metabolites were extracted from the Dowex 5W-X4 and alumina ef- 
fluents by extraction into ethyl acetate from an acidic @H 1.0) salt saturated aqueous phases. Following 
back extraction with 2.5 N NHIOH (see Methods), the resulting aqueous phase, following neutraliza- 
tion, was subjected to hplc. The mobile phase was 0.025 M potassium phosphate buffer, pH 4.0, 
containing 0.01 M citric acid and 60 mg sodium heptylsulfonate per liter. The initial methanol concen- 
tration was 12%; after the 13H]VMA and L3H]MHPG had eluted, the mobile phase was made 25% 
with respect to methanol. 
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We found a radioactivity peak eluting with 
standard MHPG only in samples subjected 
to enzymatic hydrolysis, whereas [3H]VMA 
was identified in unhydrolyzed as well as 
hydrolyzed samples. We routinely assayed 
the [3H]VMA only in unhydrolyzed samples 
since incubation with glusulase did not in- 
crease the yield of this labeled metabolite. 
This finding is in disagreement with Goodall 
and Alton’s report of a large (1.0% of ad- 
ministered radioactivity), labeled peak iden- 
tified as conjugated [3H]VMA (20). In most 
of our samples, the amount of radioactivity 
eluting in fractions that would have con- 
tained C3H]MHPE was negligible. As an- 
ticipated from previous studies (6,7,20) a 
large [3H]HVA peak was present in all 
samples, this being by far the quantitatively 
most important [p-3H]DA metabolite (Ta- 
ble 1). 
DISCUSSION 
There is little agreement in the existing 
literature on the rate at which systemi- 
cally administered labeled dopamine under- 
goes P-hydroxylation in whole animals and 
human subjects. In a number of studies of 
dopamine metabolism, the pool of /3-hydrox- 
ylated metabolites has apparently been too 
small to be resolved by the chromatographic 
procedure employed (6,7). We estimated, 
however, in rats on the basis of a tritium 
release assay that the in vivo rate of dopamine 
/3-hydroxylation was 3.4 +- 0.3%/10 min 
(11). Similarly, following the intravenous 
administration of labeled tyramine to rats, 
there is rapid accumulation of the labeled 
$-hydroxylated derivative octopamine in 
sympathetically innervated organs, such as 
heart and spleen (21). Similarly, another 
phenylethylamine DBH substrate, hydroxy- 
amphetamine, readily undergoes in vivo 
/3-hydroxylation in man. Sjoerdsma and von 
Studnitz observed that following the oral ad- 
ministration of hydroxyamphetamine to 
humans, between 4 and 9% of the adminis- 
tered drug is converted over a 24-h period 
to the P-hydroxylated product, hydroxy- 
norephedrine (22). 
The data in the present report do not agree 
well with a previous study of dopamine 
P-hydroxylation in man. Goodall and Alton 
reported that during the first 6 h following 
the administration of [14C]DA to humans, 8% 
of the administered isotope could be ac- 
counted for as excreted metabolites of [‘“Cl- 
NE (20). In the present study, however, we 
found that only 1.28 + 0.16% of the ad- 
ministered radioactivity was excreted in the 
[3H]NE metabolite pool during the first 6 h 
following the administration of isotope (Ta- 
ble 1) and the ratio of total [3H]NE metabo- 
lites/total [3H]DA metabolites was 0.029 
of: 0.005 (SEM). These estimates of [3H]NE 
metabolite excretion would be doubled if 
we had used a substrate whose label could 
not be released during the enzymatic hy- 
droxylation.3 Even with this correction, 
however, our estimate of the rate of dopa- 
mine P-hydroxylation in vivo remains much 
lower than that reported by Goodall and 
Alton. Since higher degrees of resolution 
can be achieved with hplc than with tradi- 
tional ion-exchange chromatography, our 
estimate of the [3H]NE metabolite pool is 
probably more accurate than that based on 
the older methodology. We suspect, for ex- 
ample, that the large peak of radioactivity 
(1 .O% of administered isotope) identified as 
conjugated [3H]VMA represented some in- 
terfering compound since we were unable 
to even identify this metabolite in our chro- 
matographic system. Alternatively, differ- 
ences in experimental protocol may explain 
the discrepancy between our data and that 
reported by Goodall and Alton. We gave the 
dopamine over 2 min and these previous 
investigators administered it over 4 h as a 
constant infusion. Moreover, we used [3Hl- 
DA, whereas they used [14C]DA. 
Since hplc retention time is dramatically 
altered by the polarity change caused by 
the presence of a hydroxyl group on the 
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P-position of the catechol side chain, this 
technique is ideal for the separation of NE 
from DA metabolites. Yet our attempts to 
accurately quantitate the total [3H]NE me- 
tabolite pool has been complicated by the 
presence of a number of unidentified peaks 
of radioactivity whose low hplc retention 
times suggest a high degree of polarity pos- 
sibly indicative of a hydroxyl group on the 
P-position of the molecule. In particular, the 
basis of the chromatographic behavior (rapid 
hplc elution) of the peak of radioactivity 
eluting just before [3H]DHMA (See Fig. 4) 
and the peak of radioactivity eluting just 
before [3H]VMA (see Fig. 5), one would 
predict that these labeled metabolites are 
very polar compounds and, therefore, apt 
to be [3H]NE (rather than [3H]DA) metabo- 
lites. The amount of radioactivity eluting 
in the unidentified peak prior to [3H]VMA 
approaches that eluting which [3H]VMA it- 
self, and thus would appear (if derived from 
[3H]NE) to be a quantitatively important 
metabolite. Attempts to identify this labeled 
compound, which was observed equally in 
unhydrolyzed and hydrolyzed urine, are 
currently in progress. 
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